Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $108.70 Average Price Target from Analysts

Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREGet Rating) has earned a consensus rating of “Hold” from the seventeen analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $108.70.

A number of brokerages have commented on RARE. Morgan Stanley reduced their target price on Ultragenyx Pharmaceutical from $120.00 to $118.00 and set an “overweight” rating for the company in a report on Friday, February 11th. JPMorgan Chase & Co. raised Ultragenyx Pharmaceutical from a “neutral” rating to an “overweight” rating and set a $132.00 target price for the company in a report on Friday, February 11th. The Goldman Sachs Group reduced their target price on Ultragenyx Pharmaceutical from $139.00 to $101.00 and set a “neutral” rating for the company in a report on Tuesday. StockNews.com cut Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, April 26th. Finally, Cowen reduced their target price on Ultragenyx Pharmaceutical from $124.00 to $99.00 in a report on Friday, May 6th.

RARE stock traded up $2.80 during mid-day trading on Friday, reaching $48.64. 494,529 shares of the company’s stock were exchanged, compared to its average volume of 479,510. The company has a market cap of $3.40 billion, a price-to-earnings ratio of -7.08 and a beta of 1.58. The stock’s 50 day moving average is $67.14 and its 200 day moving average is $71.60. Ultragenyx Pharmaceutical has a 12-month low of $45.20 and a 12-month high of $105.99.

Ultragenyx Pharmaceutical (NASDAQ:RAREGet Rating) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.78) by ($0.41). The business had revenue of $79.94 million for the quarter, compared to analysts’ expectations of $84.25 million. Ultragenyx Pharmaceutical had a negative return on equity of 49.18% and a negative net margin of 141.65%. The business’s revenue for the quarter was down 19.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($2.03) EPS. Analysts predict that Ultragenyx Pharmaceutical will post -7.15 earnings per share for the current year.

In other news, EVP Karah Herdman Parschauer sold 5,140 shares of the firm’s stock in a transaction on Monday, March 7th. The stock was sold at an average price of $62.95, for a total transaction of $323,563.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Erik Harris sold 2,713 shares of the firm’s stock in a transaction on Tuesday, March 1st. The stock was sold at an average price of $66.62, for a total value of $180,740.06. The disclosure for this sale can be found here. Insiders sold 22,764 shares of company stock valued at $1,504,050 over the last quarter. 6.70% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. IndexIQ Advisors LLC purchased a new position in shares of Ultragenyx Pharmaceutical during the first quarter worth $44,000. Lazard Asset Management LLC boosted its position in shares of Ultragenyx Pharmaceutical by 36.6% during the first quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company’s stock worth $64,000 after buying an additional 240 shares during the period. Alpha Paradigm Partners LLC purchased a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter worth $113,000. Advisor Group Holdings Inc. boosted its holdings in Ultragenyx Pharmaceutical by 26.6% in the third quarter. Advisor Group Holdings Inc. now owns 1,612 shares of the biopharmaceutical company’s stock valued at $146,000 after purchasing an additional 339 shares during the period. Finally, Harbor Capital Advisors Inc. purchased a new position in Ultragenyx Pharmaceutical in the first quarter valued at $169,000. Institutional investors and hedge funds own 97.49% of the company’s stock.

About Ultragenyx Pharmaceutical (Get Rating)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Further Reading

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.